StreetAlpha.app
Home › Stocks › XNCR

Xencor Inc (XNCR)

Healthcare
$34.50
▼ −2.55%
LAST CLOSE · NOV 17

Xencor develops engineered antibody drugs for cancer and autoimmune diseases and partners with other drugmakers on its technology. It last closed at $34.50 on Nov 17, down 2.55% on the day. The average 12-month price target from 9 analysts is $41.11 (+19.2% from the last close), with a high of $70.00 and a low of $21.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (7 buy, 2 hold, 0 sell).

AI Auto Pilots
Is XNCR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$200.5M
+33.5% vs a year ago
Net income
−$117.9M
−58.8% margin
EPS (diluted)
−$1.56
Free cash flow
−$176.4M
−88.0% margin
Valuation
Market cap
$2.6B
75.0M shares
P/E
–
No P/E while losing money
Price to sales
12.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$59.6M
At Sep 30
Debt
$95.1M
At Sep 30
Shareholder equity
$560.4M
Shares outstanding
75.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $275.1M$275.1MFY2021FY2022: $164.6M$164.6MFY2022FY2023: $174.6M$174.6MFY2023FY2024: $110.5M$110.5MFY2024FY2025: $125.6M$125.6MFY2025

From XNCR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
7 Buy2 Hold0 Sell
Each firm's latest rating on XNCR in the past 90 days
Average 12-month target
$41.11
▲ 19.2% upside

Based on 9 analysts who set a price target on XNCR in the past 90 days. The average target is $41.11, with a high of $70.00 and a low of $21.00, compared with the last close of $34.50.

Low $21.00Avg $41.11High $70.00
Blue marker: last close $34.50
Highest target$70.00
Average target$41.11
Lowest target$21.00
Latest rating changes
Cantor FitzgeraldTarget raised
Nov 5Buy$44 → $70
Truist SecuritiesTarget raised
Oct 27Buy$29 → $40
RBC CapitalTarget raised
Oct 27Buy$20 → $43
Wells FargoMaintained
Oct 27Buy$44
WedbushTarget raised
Oct 27Buy$30 → $45
DateFirmActionRatingPrice target
Nov 5Cantor FitzgeraldTarget raisedBuy$44 → $70
Oct 27Truist SecuritiesTarget raisedBuy$29 → $40
Oct 27RBC CapitalTarget raisedBuy$20 → $43
Oct 27Wells FargoMaintainedBuy$44
Oct 27WedbushTarget raisedBuy$30 → $45
Loading…

Technical Analysis

XNCR · as of the Nov 17 close · updated after every close
Uptrend

The stock is 5% above its 20 day and 20% above its 50 day average. It is 47% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $33.92, and the nearest resistance the Pivot at $34.81.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$40.5852 week high+17.6%
$40.58Swing high (Nov 11)+17.6%
$35.38Pivot R1+2.6%
$34.81Pivot+0.9%
$34.50Last close
$33.92Pivot S1−1.7%
$32.6320 day average−5.4%
$27.7050 day average−19.7%
$25.81Swing low (Aug 28)−25.2%
$24.49100 day average−29.0%
$18.33200 day average−46.9%
$10.3852 week low−69.9%
Indicators
RSI (14)58.21Middle of its rangeNeutral
MACD2.97Above its signal lineBullish
Stochastic59.6Middle of its rangeNeutral
ADX (14)39.1Trending up
Williams %R-50.8Oversold below −80, overbought above −20Neutral
CCI (20)35.8Oversold below −100, overbought above 100Neutral
Rate of change+12.6%Change over 10 sessionsBullish
ATR (14)$2.02Typical daily range, 5.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for XNCR

What happened before

See how XNCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XNCR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XNCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XNCR in the last 90 days.

Loading…

See today’s whale options flow across the market →

XNCR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲119 buying vs 97 selling
  • ▲Held by funds +4.5 pts
  • ▲Funds holding +26
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234208+12.5%
In funds' top 1042+100.0%
Held by funds116.7%112.2%+4.5 pts
New / increased46 / 7330 / 84+4.4%
Reduced / sold out77 / 2056 / 24+21.3%
Put/call ratio1.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XNCR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XNCR is in one of them and how their past XNCR trades turned out.

XNCR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XNCR in an article yet. Here's the latest on the wider market.

XNCR Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Sep 22
Who traded XNCR · since 2026
Latest 1 filing
$1K – $15KTraded Jul 29, 2026Filed Sep 22, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KJul 29, 2026Sep 22, 202655 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Xencor

Xencor is a biopharmaceutical company based in Pasadena, California, that designs engineered antibody drugs. Its work focuses on cancer and autoimmune diseases, and it uses its own protein engineering technology to build antibody drug candidates, several of which are in clinical trials. The company also licenses its antibody design technology to pharmaceutical and biotechnology partners, who may develop or market the resulting medicines.

Headquarters
Pasadena, CA